drugset / Trial / NCT00618124

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

NCT00618124

Phase 1 Completed 77 enrolled Pfizer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors

Timeline

Start
2005-05
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject Sunitinib Small molecule Oral

Indications